臺大公衛學院-流行病學所;臺大醫院-內科部;臺大醫院-醫學研究部;臺大醫學院;Chang C.H.Hsiao C.F.Yeh Y.M.Chang G.C.Tsai Y.H.Chen Y.M.Huang M.S.Chen H.L.Li Y.J.PAN-CHYR YANGChen C.J.Hsiung C.A.Su W.C.2014-02-142018-07-112014-02-142018-07-112013http://ntur.lib.ntu.edu.tw//handle/246246/259280Lung cancer is the leading cause of cancer death worldwide as well as in Taiwan. Interleukin-6 (IL-6) is a multifunctional cytokine and has been implicated in tumor progression. This study recruited 245 patients with advanced (Stage 3B/4) nonsmall cell lung cancer (NSCLC) that had received chemotherapy, to evaluate associations between IL-6 and lung cancer-specific survival. Among these subjects, 112 gave blood samples before and 133 after the start of chemotherapy. Plasma IL-6 was measured using an enzyme linked-immunosorbent assay. The 33rd and 66th percentiles of IL-6 concentrations were 2.01 and 25.16 for the 245 patients and were defined as the cutoff points for dividing the patients into low, intermediate and high groups. Kaplan-Meier and Cox proportional-hazard models were used to evaluate the relationship between the IL-6 level and survival time. Results after adjusting for age, sex, smoking history, histologic type and stage of lung cancer revealed a significant relationship. For all patients, the hazard ratio with high IL-6 levels for lung cancer-specific survival was 2.10 [95% confidence interval (CI) = 1.49 2.96] compared with low IL-6 levels. The hazard ratio for patients who were recruited before and after the start of chemotherapy was1.25 (95% CI = 0.73 2.13) and 3.66 (95% CI = 2.18 6.15), respectively. Patients with high circulating IL-6 also responded poorly to chemotherapy. Therefore, a high level of circulating IL-6 was associated with an inferior response and survival outcome in NSCLC patients treated with chemotherapy.99 bytestext/htmllung cancersurvivalInterleukin-6prognostic factor[SDGs]SDG3antineoplastic agent; interleukin 6; age distribution; anamnesis; article; blood sampling; cancer chemotherapy; cancer prognosis; cancer specific survival; cancer staging; cancer survival; enzyme linked immunosorbent assay; gender; histopathology; human; Kaplan Meier method; lung non small cell cancer; major clinical study; priority journal; protein blood level; protein determination; protein expression; smoking; survival time; treatment outcome; Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Enzyme-Linked Immunosorbent Assay; Female; Humans; Interleukin-6; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Survival Rate; Tumor Markers, Biological10.1002/ijc.27892http://ntur.lib.ntu.edu.tw/bitstream/246246/259280/1/index.html